PERINTAH RACUN (PINDAAN SENARAI RACUN) (NO. 2) 2017

dengan memasukkan selepas butiran “Bleomycin; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Bortezomib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Celecoxib” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Dapsone” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan menggantikan butiran “Erythropoeitin” dengan butiran “Erythropoietin”;

dengan memasukkan selepas butiran “Exenatide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan menggantikan butiran “Fenpiramide; its salts” dengan butiran “Fenpipramide; its salts”;

5

dengan memasukkan selepas butiran “Fesoteradine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dalam butiran “Hydroquinone” dengan menggantikan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

Names

dengan memasukkan selepas butiran “Idarubicin” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan menggantikan butiran “Iobitriol” dengan butiran “Iobitridol”;

dengan memasukkan selepas butiran “Lenograstim” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Levamisole; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dalam butiran “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” dengan memasukkan selepas butiran “Ropivacaine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Lung Phospholipid” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Nitrophenols, ortho, meta and para” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Olanzapine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Paclitaxel” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Panitumumab” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Pegvisomant” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan menggantikan butiran “Phenethylamine” dengan butiran “Phenethylamine unless specified elsewhere in the

List”;

12

dalam butiran “Phosphorus” dengan menggantikan butir-butir yang berhubungan dengannya dengan butir-butir yang berikut:

Names

dengan memasukkan selepas butiran “Pirenzepine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Piroxicam” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Polymethylene bis trimethyl-ammonium salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Sildenafil; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Ulipristal” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dengan memasukkan selepas butiran “Vecuronium; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

Names

dalam Lampiran kepada Senarai Racun—

dalam senarai “Anaesthetics:”, dengan memasukkan selepas butiran “Ropivacaine” butiran “Tetracaine”;

dalam senarai “Analeptics and Central Stimulants:”, dengan memasukkan selepas butiran “Cathinone (DD)” butiran

“Dexamphetamine (DD); its salts”;

dalam senarai “Anti-asthmatics:”, dengan memasukkan selepas butiran “Tulobuterol” butiran “Umeclidinium”;

dalam senarai “Antibiotics:”—

dengan menggantikan butiran “Antibiotics, all substances of; their synthetic preparations; their salts” dengan butiran “Antibiotics, all substances of; their synthetic preparations; their salts; unless stated elsewhere in the

List”; dan 16

dengan memasukkan selepas butiran “Avoparcin” butiran “Chloramphenicols and other substances structurally derived therefrom, their salts; their esters”;

dalam senarai “Anticholinergics:”—

dengan memasukkan sebelum butiran “Atropine” butiran “Aclidinium bromide”;

dengan memasukkan selepas butiran “Cycrimine; its salts” butiran “Darifenacin”;

dengan memasukkan selepas butiran “Homatropine” butiran “Hyoscine”;

dengan menggantikan butiran “Solanaceous alkaloids unless specified elsewhere in this List” dengan butiran

“Solanaceous alkaloids unless specified elsewhere in the List”; dan

dengan memasukkan selepas butiran “Timepidium; its salts” butiran “Tiotropium bromide”;

dalam senarai “Anticonvulsants:”, dengan memasukkan selepas butiran “Lamotrigine” butiran “Levetiracetam”;

dalam senarai “Antidepressants:”, dengan menggantikan butiran “Clofexamine; its salts” dengan butiran

“Clofexamide; its salts”;

dalam senarai “Antidiabetics:”—

17

dengan memasukkan selepas butiran “Lixisenatide” butiran “Luseogliflozin”; dan

dengan memotong butiran “Tiotropium bromide”;

dalam senarai “Antihistamines:”—

dengan menggantikan butiran “Fexofenadine, its salts”; dengan butiran “Fexofenadine”; dan

dengan menggantikan butiran “Levocabastine”; dengan butiran “Levocabastine; its salts”;

dalam senarai “Antihypertensives:”—

dengan memasukkan selepas butiran “Aliskiren” butiran “Amlodipine”;

dengan memasukkan selepas butiran “Felodipine” butiran “Fimasartan”;

dengan memasukkan selepas butiran “Nilvadipine” butiran “Nimodipine”; dan

dengan memasukkan selepas butiran “Olmesartan medoxomil” butiran “Oxyclonazide”;

18

dalam senarai “Antineoplastic agents and Immunosuppressants:”—

dengan memasukkan selepas butiran “Bicalutamide” butiran “Blinatumomab”;

dengan menggantikan butiran “Emestane” dengan butiran “Exemestane”;

dengan memasukkan selepas butiran “Lapatinib Ditosylate” butiran “Lenvatinib”;

dengan menggantikan butiran “Leoprolide; its salts” dengan butiran “Leuprolide; its salts”;

dengan memasukkan selepas butiran “Nilotinib” butiran “Nivolumab”;

dengan memasukkan selepas butiran “Ofatumumab” butiran “Olaparib”;

dengan memasukkan selepas butiran “Paclitaxel” butiran “Palbociclib”;

dengan memasukkan selepas butiran “Panitumumab” butiran “Panobinostat”;

dengan memasukkan selepas butiran “Pazopanib” butiran “Pembrolizumab”;

19

dengan memasukkan selepas butiran “Pertuzumab” butiran yang berikut:

“Pirfenidone

Pomalidomide”; dan

dengan memasukkan selepas butiran “Teropterin” butiran “Thalidomide”;

dalam senarai “Antitussive:”, dengan menggantikan butiran “Levodropizine; its salts” dengan butiran

“Levodropropizine; its salts”;

dalam senarai “Antiviral agents:”—

dengan memasukkan selepas butiran “Acyclovir” butiran “Adefovir dipivoxil”;

dengan menggantikan butiran “Amantadine and other substances structurally derived therefrom; their salts”

dengan butiran “Amantadine and other substances structurally derived therefrom; their salts unless specified elsewhere in the List”;

dengan menggantikan butiran “Nelfinavir” dengan butiran “Nelfinavir; its salts”; dan dengan memasukkan selepas butiran “Trifluridine” butiran “Tromantadine; it salts”;

20

dalam senarai “Hallucinogens”, dengan menggantikan butiran “2-amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane or STP or DOM (DD)” dengan butiran “2-Amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane (DD)”;

dalam senarai “Hypnotics and Sedatives:”, dengan memotong butiran “Thalidomide”;

dalam senarai “Sympathomimetic amines”, dengan menggantikan butiran “Adrenaline and other substances structurally derived from Phenethylamine by substitution in the aliphatic part or by ring closure therein (or by both substitution and closure) or by substitution in the aromatic ring with or without substitution in the nitrogen atom unless otherwise specified elsewhere in the List or both; any salt of any substance falling within this item” dengan butiran “Adrenaline”;

dalam senarai “Vasodilators:”, dengan memotong butiran “Adenosine; its salts”; dan

dalam senarai “Miscellaneous:”—

dengan memotong butiran “Adefovir Dipivoxil”;

dengan menggantikan butiran “Amifostin; its salts; its esters” dengan butiran “Amifostine; its salts; its esters”;

21

dengan memasukkan selepas butiran “Boric acid and Sodium borate” butiran “Botulinum toxin; natural or synthetic”;

dengan menggantikan butiran “Cabergolide” dengan butiran “Cabergoline”;

dengan memasukkan selepas butiran “Carperidine; its salts” butiran “Cerebrolysin”;

dengan memasukkan selepas butiran “Etidronate disodium” butiran “Ezetimibe”;

dengan menggantikan butiran “Gelsemium, alkaloids of 8-[N-(2-hydroxyethyl) methylamino]-1, 3,

7-trimethylxanthine” dengan butiran yang berikut:

“Gelsemium, alkaloids of 8-[N-(2-hydroxyethyl)-methyl-amino]-1, 3, 7 trimethylxanthine”;

dengan memasukkan selepas butiran “Ibandronic Acid” butiran “Idarucizumab”;

dengan menggantikan butiran “Mercury; its oxides; its inorganic and organic compounds unless specified elsewhere in the List” dengan butiran “Mercury”;

dengan menggantikan butiran “Nalidixic acid” dengan butiran “Nalidixic acid and other substances structurally derived therefrom; its salts”;

22

dengan memasukkan selepas butiran “Nicotine” butiran “Nicotinic acid”;

dengan memasukkan selepas butiran “Penicillamine; its salts” butiran “Pentosan”;

dengan menggantikan butiran “Piper methysticum” dengan butiran “Piper methysticum (kava-kava); its salts”;

dengan memasukkan selepas butiran “Pirfenoxone; its salts” butiran “Pitavastatin calcium”;

dengan memasukkan selepas butiran “Radium and other radioactive substances for therapeutic use or diagnostic use” butiran “Rafoxanide”;

dengan menggantikan butiran “Sibutramine hydrochloride” dengan butiran “Sibutramine”; dan

dengan memasukkan selepas butiran “Sibutramine” butiran “Silodosin”.

Dibuat 4 Mei 2017

[KKM.R.600-1/1/56; PN(PU2)172/XIV]

DATUK SERI DR. S. SUBRAMANIAM

Menteri Kesihatan

23

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) (NO. 2) ORDER 2017

In the Poisons List—

by inserting after the item “Acitretin” and the particulars relating to it the following item:

Names

by inserting after the item “Bleomycin; its salts” and the particulars relating to it the following item:

Names

by inserting after the item “Bortezomib” and the particulars relating to it the following item:

Names

by inserting after the item “Celecoxib” and the particulars relating to it the following item:

Names

by inserting after the item “Dapsone” and the particulars relating to it the following item:

Names

by substituting for the item“Erythropoeitin” the item “Erythropoietin”;

by inserting after the item “Exenatide” and the particulars relating to it the following item:

Names

by substituting for the item“Fenpiramide; its salts” the item “Fenpipramide; its salts”;

26

by inserting after the item “Fesoteradine” and the particulars relating to it the following item:

Names

in the item “Hydroquinone” by substituting for the particulars relating to it the following particulars:

Names

by inserting after the item “Idarubicin” and the particulars relating to it the following item:

Names

by substituting for the item“Iobitriol” the item “Iobitridol”;

by inserting after the item “Lenograstim” and the particulars relating to it the following item:

Names

by inserting after the item “Levamisole; its salts” and the particulars relating to it the following item:

Names

in the item “Local anaesthetics; the following: their salts; their homologues and analogues; their molecular compounds:” by inserting after the item “Ropivacaine” and the particulars relating to it the following item:

Names

by inserting after the item “Lung Phospholipid” and the particulars relating to it the following item:

Names

by inserting after the item “Nitrophenols, ortho, meta and para” and the particulars relating to it the following item:

Names

by inserting after the item “Olanzapine” and the particulars relating to it the following item:

Names

by inserting after the item “Paclitaxel” and the particulars relating to it the following item:

Names

by inserting after the item “Panitumumab” and the particulars relating to it the following item:

Names

by inserting after the item “Pegvisomant” and the particulars relating to it the following item:

Names

by substituting for the item “Phenethylamine” the item “Phenethylamine unless specified elsewhere in the List”;

in the item “Phosphorus” by substituting for the particulars relating to it the following particulars:

Names

by inserting after the item “Pirenzepine; its salts” and the particulars relating to it the following item:

Names

by inserting after the item “Piroxicam” and the particulars relating to it the following item:

Names

by inserting after the item “Polymethylene bis trimethyl-ammonium salts” and the particulars relating to it the following item:

Names

by inserting after the item “Sildenafil; its salts” and the particulars relating to it the following item:

Names

by inserting after the item “Ulipristal” and the particulars relating to it the following item:

Names

by inserting after the item “Vecuronium; its salts” and the particulars relating to it the following item:

Names

in the Appendix to the Poisons List —

in the list of “Anaesthetics:”, by inserting after the item “Ropivacaine” the item“Tetracaine”;

in the list of “Analeptics and Central Stimulants:”, by inserting after the item “Cathinone (DD)” the item“Dexamphetamine (DD); its salts”;

in the list of “Anti-asthmatics:”, by inserting after the item “Tulobuterol” the item “Umeclidinium”;

35

in the list of “Antibiotics:”—

by substituting for the item “Antibiotics, all substances of; their synthetic preparations; their salts” the item

“Antibiotics, all substances of; their synthetic preparations; their salts; unless stated elsewhere in the List”; and by inserting after the item “Avoparcin” the item “Chloramphenicols and other substances structurally derived therefrom, their salts; their esters”;

in the list of “Anticholinergics:”—

by inserting before the item “Atropine” the item “Aclidinium bromide”;

by inserting after the item “Cycrimine; its salts” the item “Darifenacin”;

by inserting after the item “Homatropine” the item “Hyoscine”;

by subtituting for the item “Solanaceous alkaloids unless specified elsewhere in this List” the item “Solanaceous alkaloids unless specified elsewhere in the List”; and by inserting after the item “Timepidium; its salts” the item “Tiotropium bromide”;

in the list of “Anticonvulsants:”, by inserting after the item “Lamotrigine” the item “Levetiracetam”;

36

in the list of “Antidepressants:”, by substituting for the item “Clofexamine; its salts” the item “Clofexamide; its salts”

in the list of “Antidiabetics:”—

by inserting after the item “Lixisenatide” the item “Luseogliflozin”; and by deleting the item “Tiotropium bromide”;

in the list of “Antihistamines:”—

by substituting for the item “Fexofenadine, its salts” the item “Fexofenadine”; and by substituting for the item “Levocabastine” the item “Levocabastine; its salts”;

in the list of “Antihypertensives:”—

by inserting after the item “Aliskiren” the item “Amlodipine”;

by inserting after the item “Felodipine” the item “Fimasartan”;

by inserting after the item “Nilvadipine” the item “Nimodipine”; and

37

by inserting after the item “Olmesartan medoxomil” the item “Oxyclonazide”;

in the list of “Antineoplastic agents and Immunosuppressants:”—

by inserting after the item “Bicalutamide” the item “Blinatumomab”;

by substituting for the item “Emestane” the item “Exemestane”;

by inserting after the item “Lapatinib Ditosylate” the item “Lenvatinib”;

by substituting for the item “Leoprolide; its salts” the item “Leuprolide; its salts”;

by inserting after the item “Nilotinib” the item “Nivolumab”;

by inserting after the item “Ofatumumab” the item “Olaparib”;

by inserting after the item “Paclitaxel” the item “Palbociclib”;

by inserting after the item “Panitumumab” the item “Panobinostat”;

by inserting after the item “Pazopanib” the item “Pembrolizumab”;

38

by inserting after the item “Pertuzumab” the following items:

“Pirfenidone

Pomalidomide”; and by inserting after the item “Teropterin” the item “Thalidomide”;

in the list of “Antitussive:”, by substituting for the item “Levodropizine; its salts” the item “Levodropropizine; its salts”;

in the list of “Antiviral agents:”—

by inserting after the item “Acyclovir” the item “Adefovir dipivoxil”;

by substituting for the item “Amantadine and other substances structurally derived therefrom; their salts” the item “Amantadine and other substances structurally derived therefrom; their salts unless specified elsewhere in the List”;

by substituting for the item “Nelfinavir” the item “Nelfinavir; its salts”; and by inserting after the item “Trifluridine” the item “Tromantadine; it salts”;

39

in the list of “Hallucinogens”, by substituting for the item“2-amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane or

STP or DOM (DD)” the item “2-Amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane (DD)”;

in the list of “Hypnotics and Sedatives:”, by deleting the item“Thalidomide”;

in the list of “Sympathomimetic amines”, by substituting for the item“Adrenaline and other substances structurally derived from Phenethylamine by substitution in the aliphatic part or by ring closure therein (or by both substitution and closure) or by substitution in the aromatic ring with or without substitution in the nitrogen atom unless otherwise specified elsewhere in the List or both; any salt of any substance falling within this item” the item

“Adrenaline”;

in the list of “Vasodilators:”, by deleting the item “Adenosine; its salts”; and

in the list of “Miscellaneous:”—

by deleting the item “Adefovir Dipivoxil”;

by substituting for the item “Amifostin; its salts; its esters” the item “Amifostine; its salts; its esters”;

by inserting after the item “Boric acid and Sodium borate” the item “Botulinum toxin; natural or synthetic”;

by substituting for the item “Cabergolide” the item “Cabergoline”;

40

by inserting after the item “Carperidine; its salts” the item “Cerebrolysin”;

by inserting after the item “Etidronate disodium” the item “Ezetimibe”;

by substituting for the item “Gelsemium, alkaloids of 8-[N-(2-hydroxyethyl) methylamino]-1, 3,

7-trimethylxanthine” the following items:

“Gelsemium, alkaloids of 8-[N-(2-hydroxyethyl)-methyl-amino]-1, 3, 7 trimethylxanthine”;

by inserting after the item “Ibandronic Acid” the item “Idarucizumab”;

by substituting for the item “Mercury; its oxides; its inorganic and organic compounds unless specified elsewhere in the List” the item “Mercury”;

by substituting for the item “Nalidixic acid” the item “Nalidixic acid and other substances structurally derived therefrom; its salts”;

by inserting after the item “Nicotine” the item “Nicotinic acid”;

by inserting after the item “Penicillamine; its salts” the item “Pentosan”;

41

by substituting for the item “Piper methysticum” the item “Piper methysticum (kava-kava); its salts”;

by inserting after the item “Pirfenoxone; its salts” the item “Pitavastatin calcium”;

by inserting after the item “Radium and other radioactive substances for therapeutic use or diagnostic use”

the item “Rafoxanide”;

by substituting for the item “Sibutramine hydrochloride” the item “Sibutramine”; and

by inserting after the item “Sibutramine” the item “Silodosin”.

Made 4 May 2017

[KKM.R.600-1/1/56; PN(PU2)172/XIV]

DATUK SERI DR. S. SUBRAMANIAM

Minister of Health